COMMUNIQUÉS West-GlobeNewswire

Lytus Technologies Holdings PTV. Ltd. announces 1 for 60 Reverse Stock Split

21/02/2024 - 15:19

Dubai, UAE, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Lytus Technologies Holdings PTV. Ltd. (the “Company”) (Nasdaq:LYT), a leading global technology-driven services company, today announced that on February 5 th , 2024, the [...]

Notice for the Annual General Meeting of Novo Nordisk A/S

21/02/2024 - 15:03

Bagsværd, Denmark, 21 February 2024 – The Annual General Meeting of Novo Nordisk A/S will be held on: Thursday 21 March 2024 at 14.00 (CET) The Annual General Meeting is held as a partially electronic general meeting. [...]

Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025

21/02/2024 - 15:00

VANCOUVER, British Columbia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey. A recent exclusive [...]

Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

21/02/2024 - 15:00

Santhera's Study Reports the Results of the 48-Week Treatment with Vamorolone in Patients with Duchenne Muscular Dystrophy (DMD) in the VISION-DMD Study, Supporting the Long-Term Efficacy and Safety Profile of [...]

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

21/02/2024 - 14:52

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced [...]

SFWJ dba MedCana Adding to Portfolio with Acquisition of Cutting-Edge Cannabis Company

21/02/2024 - 14:45

Targeted company, based in Colombia, holds a unique cannabis genetics license AUSTIN, Texas, Feb. 21, 2024 (GLOBE NEWSWIRE) -- via IBN – SFWJ dba MedCana , a leading holding company in the cannabis industry, reveals it [...]

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

21/02/2024 - 14:30

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms [...]

Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv

21/02/2024 - 14:30

– Innovative design enables five-minute pegfilgrastim-cbqv delivery time – – Unique, automatic, retractable needle mechanism engineered to maximize safety and comfort for cancer patients receiving UDENYCA ® – REDWOOD [...]

Diagnostics Industry Leader Gary Huff Appointed to Biomerica Strategic Advisory Board

21/02/2024 - 14:19

Mr. Huff was the Former CEO of LabCorp Diagnostics and joins with significant executive experience and a proven track record in medical diagnostics and healthcare IRVINE, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- [...]

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

21/02/2024 - 14:15

HANOVER, MD, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

21/02/2024 - 14:01

Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. ( [...]

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

21/02/2024 - 14:00

CAMBRIDGE, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ( [...]

Route 92 Medical Announces Completion of Enrollment in the SUMMIT MAX Clinical Trial

21/02/2024 - 14:00

Randomized controlled trial designed to evaluate the safety and effectiveness of the Route 92 Medical 0.088” HiPoint Reperfusion Catheter, part of the Monopoint Reperfusion System SAN MATEO, Calif., Feb. 21, 2024 (GLOBE [...]

REPEAT: New report exposes harmful impact of Ford government’s privatization scheme on local public hospitals: Health Coalition

21/02/2024 - 14:00

Attn: Assignment Editor TORONTO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- As the Ford government counters horror stories about unprecedented emergency department wait times, burgeoning deficits, and an unrelenting staffing [...]

BrainsWay to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

21/02/2024 - 14:00

BURLINGTON, Mass. and JERUSALEM, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental [...]

VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

21/02/2024 - 14:00

BRIDGEWATER, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative, and differentiated [...]

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21/02/2024 - 14:00

CONSHOHOCKEN, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today [...]

BioSyent Named to 2024 TSX Venture 50

21/02/2024 - 14:00

MISSISSAUGA, Ontario, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that it has been named to the 2024 TSX Venture 50 list as one of the top [...]

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

21/02/2024 - 14:00

- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind assay to measure target [...]